Latest from MSKCC

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a basket study of taselisib in patients with PIK3CA-mutated solid tumors.
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses resistance mutations in patients with non–small cell lung cancer (NSCLC).
Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).
Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role tumor mutational burden (TMB) plays in determining combination therapies for patients with non–small cell lung cancer (NSCLC).
Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.
Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.
Women with HER2-negative metastatic breast cancer associated with a germline BRCA mutation may have a slight survival advantage with a PARP inhibitor instead of chemotherapy.
Anas Younes, MD, chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Publication Bottom Border
Border Publication
x